Avanos Q3 Earnings Meet Estimates, Sales Miss, Gross Margin Contracts
Avanos Medical, Inc. AVNS reported third-quarter 2024 adjusted earnings per share (EPS) from continuing operations of 36 cents, up 20% year over year. The bottom line met the Zacks Consensus Estimate.
Avanos Medical Inc. (AVNS) Q3 2024 Earnings Call Transcript
Avanos Medical Inc. (NYSE:AVNS ) Q3 2024 Results Conference Call October 30, 2024 9:00 AM ET Company Participants Scott Galovan - Vice President of Strategy & Corporate Development Gary Blackford - Chairman Michael Greiner - Senior VP, CFO & Chief Transformation Officer Conference Call Participants Kristen Stewart - CL King Danny Stauder - Citizens JMP Operator Good morning, ladies and gentlemen, and welcome to the Avanos Medical, Avanos Third Quarter 2024 Earnings Call. [Operator Instructions] This call is being recorded on Wednesday, October 30, 2024.
Avanos Medical (AVNS) Q3 Earnings Meet Estimates
Avanos Medical (AVNS) came out with quarterly earnings of $0.36 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.30 per share a year ago.
Avanos Medical (AVNS) Upgraded to Strong Buy: What Does It Mean for the Stock?
Avanos Medical (AVNS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Should Value Investors Buy Avanos Medical (AVNS) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Reasons to Add Avanos Medical Stock in Your Portfolio Now
AVNS's strong product line and focus on R&D raise optimism about the stock.
Are Investors Undervaluing Avanos Medical (AVNS) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Why Avanos Medical (AVNS) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Avanos Medical Stock May Gain From Brand Partnership With NFL
AVNS' GAME READY announces a paid partnership with NFL defensive end and San Francisco 49ers star, Nick Bosa.
Is Avanos Medical (AVNS) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should Value Investors Buy Avanos Medical (AVNS) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Avanos (AVNS) Q2 Earnings Top Estimates, Gross Margin Contracts
Strength in Avanos' (AVNS) Digestive Health segment drives its second-quarter performance.
